Selecting the Right Modality for the Right Kidney Target to Convert Novel Biology into Developable Medicines
12:00 pm - Wednesday 17th March 2027
- Comparing small molecules, antibodies, RNA, gene editing and gene therapy against specific target classes
- Evaluating durability, reversibility, safety and delivery requirements during modality selection
- Determining when biological novelty justifies the additional development complexity of advanced modalities